-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ORL95Qe9NxpxXPVx6+CEPwVO/Wi0Jel8eN0XtcUfvBVviUSFlRy0hENnQMIsL55d jVqHecoTNMBbTXTKmij7oA== 0000950103-06-001070.txt : 20060411 0000950103-06-001070.hdr.sgml : 20060411 20060411141053 ACCESSION NUMBER: 0000950103-06-001070 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20060411 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060411 DATE AS OF CHANGE: 20060411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 06753295 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp02412_8k.htm
 
 
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
 
Washington, D.C. 20549 
 
FORM 8-K
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):  April 11, 2006

Shire plc
(Exact name of registrant as specified in its charter)
 
England and Wales
(State or other jurisdiction of incorporation)

0-29630   98-0484822
(Commission File Number)   (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
(Address of principal executive offices) (Zip code)
   
Registrant’s telephone number, including area code 44 1256 894 000

 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 8.01. Other Events

     Shire plc has issued the press releases attached as Exhibit 99.01 and Exhibit 99.02 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

                 (c) Exhibits. The following exhibits are filed herewith:

99.01 Press Release dated April 11, 2006
99.02  Press Release dated April 11, 2006




SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



SHIRE PLC
     
By:  /s/ A C Russell
 
  Name: Angus Russell
  Title: Chief Financial Officer

Dated: April 11, 2006





EXHIBIT INDEX

 

Number   Description
99.01   Press Release dated April 11, 2006
99.02    Press Release dated April 11, 2006




EX-99.1 2 dp02412_ex9901.htm

    EXHIBIT 99.01
  Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
     
  Press Release  
     

11 April 2006

Shire plc (the “Company”)

The Company announces that, on 11 April 2006, it was notified, pursuant to sections 198 to 202 of the Companies Act 1985, that, on 10 April 2006, Prudential plc was interested in 15,289,527 ordinary shares of £0.05 each in the capital of the Company. This holding represents 3.07 per cent of the issued ordinary share capital of the Company.

T May
Company Secretary

For further information please contact:    
         
Investor Relations   Cléa Rosenfeld (Rest of the World)    +44 1256 894 160
  Brian Piper (North America)    +1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system, gastrointestinal, general products and human genetic therapies - all being areas in which Shire has a commercial presence. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. Shire’s strategy is to develop and market products for specialty physicians. Shire’s in-licensing and merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above





GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``T)"@L*"`T+"@L.#@T/$R`5$Q(2 M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__ MVP!#`0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/ M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P``1"``Z`,@#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#TZBBB@`HH MK'\4:W'HFE22AT^TN-L"'N?7'H.M-)R=D!-JNO:9I`Q>W2K)C(C7YG/X"N"-0D MA!A-O98!QYA\R4_[Q'`_X#^M=7LJ3V+DGQ&M@GR:;,7]&D`'Y\U>LM M<\07\'VJTTRPFA[JEV"WTST!^M<1K7A?4]&B,]RL;&V0,],@\BJ_A_5 MYM&U2*YCE?\)58PZ?]IOXYK5TF\B2%D+, MCXSCCMCG-/TWQ5I.J7J6=I)(TS@D!HR!P,]:P?B%!&FD)<1MN-S=JY(]!&0/ MT%<_X#_Y&RU_W9/_`$$UFJ47!R*YG>QZS1117*61W$R6]O+/*2$B0NQ`SP!D MUSW_``G>@_\`/:;_`+\FMS4H7N=,NK>+&^6%T7)P,E2!7FG_``@6N_W;7_O[ M_P#6K:E&$E[S)DWT/48)DN+>.>,DI(H=<^A&13ZKZ?"]OIUM!)C?%$B-CID` M"K%9,H****0!1110`4444`%%%%`!1110`445S7B#Q#+#=II&B*)M3E.">JQ# MW]_Y=ZJ,7)V0F[$OB;Q`^F".TTY$N-2F8!8>25!SS@5@ZK;3:'IT>N:@GV[5 M9V"YN,%+.+J=RVKQ:E=.T\R2K(=YZX.<>PKV#3=7L-4B#V M5U%(V,E`WS+]0>:\KUSPSJ.CS-OA::W_`(9HU)&/?T-8ZL58,I((Z$&NJ=.- M5)IF:;CN>Y7]I'?V,]I-]R9"A/IGO^%#;B*T\10W%PX2*..1F9N@&PUUOQ,_Y`EK_U\#_T M%J\_TRRDU'4;>SBX:9PN?0=S^`YK6EK2U)E\1N:GXXUB\D86TBVD6>%C&6Q[ ML?Z8J"S\9:[:L,W?GKGE9D#9_'K^M=O%X%T%(0DD,LK8Y=I6!_3`K@/%&D)H MFLO:1.S1%!)&6ZX/K^(-%.5*?NI`U):GI=GK)O\`PK)JD(5)5@=BHY".H/'Z M5P?_``G6N_\`/6'_`+]"K?@JYD.A:]:$YC6W:11Z$JP/\A7'4J=**N M!6!XT^]I'_8.C_K6%8V]S?7$=C:AF>9QA`>">>3]`3^M.-*+AL',[FS?>,]< MNW)2Z%LF>$A4#'XGFN[37!8>#[74[V023/;H0&.#*Y7..!63;_#JR$0^TWUP MTF.3&%49_$&N.\07AFO%LXY2]K8+]G@SW"\%OJ6G4LH]!W<=R_>^-]; MNB?*F2V0_P`,2#/YG)JO;>+]>MFR+]I!W650P/Z9KH/"'A"SO--34-41I/-R M8XMQ4!<]3CDYK3UOP3IL]E*^FV_D72*2@1CM<^A!H$_$JZY` M\=QY45Y&>8T)^9>/F`/N<=ZZ*O#;"]GTZ^BN[=BLL39^OJ#['I7MEG)-)U6[^RV5P7EVEMIC9>!]1 M4]]HNEZ@"+NQ@D)_BVX;\QS7C^DZC-I6HPWMO@O&>5/1AW!KTFP\!,9)[F=J_P_MFB:329GCD`)\J0[E;V!ZC]:\[(* MDJPP1P0:]0U/QYI5M$18E[N4C@!2J@^Y/]*\Q=FED+'EG.3[DUO0Y[>\1*W0 MZK5KQKSX>Z8SDEXKDQ$GO@-C],54\!C_`(JRU]ED_P#0#6EXAT]],\!Z9;S* M5E\_?(#V)#''X=*SO`?_`"-EK_NO_P"@FDK>SE;S']H]9KS/XE_\AZW_`.O4 M?^A-7IE>9_$O_D/6W_7J/_0FKGP_QE3V(_!7_'AKW_7D?Y-7*5U?@K_CPU__ M`*\C_)JY2NR/Q2,WLCI?&GWM(_[!T?\`6K/PVB5]?FD/6.W./Q8"JWC3[VD? M]@Z/^M7?AG_R&;K_`*]__9A6;_@L:^(]&ESY+[>NTXKP89QSUKWRO&O%&EOI M.N7$)0B%V,D)[%3_`(=/PK+"M7:*F);Z3KTUO'+;6MXT+*"A7."/:I?[%\2? M\^=__P"/5TW@KQ59P:H>%H9[?PY90W4;1RHA#* MPP1R*V+2OMC3RR3R>!UKTF`2+!&)V5Y0HWLHP">^!6=> M4K)2'!+H/HHHKF+"BBB@#E]?\&V^J7C7UM<1DG/DR_=_!NH_&N>E\%^((VP+(. M/595_P`:];HK:.(FB7!'DT/@C7Y2-UJD0]7E7^A-=;H'@>UTZ:.ZO93MZ=#;V1B#I-O/F,0,8(]#ZUB>%_". MJ:5KL-[=-;&)`P.QR3RI'I[UW=%2JLE'E6P^57N%<;XQ\,:CK>J0W-DT`C2$ M(?,<@YW,?0^M=E14PFX.Z!JYQ7ASPMJ6F6NJ1W+6Y:ZMS%'L]8?\` MP@&M_P!^S_[^G_XFO4:*T5>:;8N5'#^(_">IZFU@;9KM`4DBV#RW).<@^@]*["BDZTN7E#E5[A6;KFB6>N6@@N@59 M3F.5?O(?\/:M*BLTVG=%'E]]X!U>"5A:&&YCS\I#!&_$'_&J\7@C7Y&`:VCC M'J\JX_0FO6**W6)G8CD1S7AGPC;Z*XNIY//O,8#8PJ9ZX']:Z6BBL92 EX-99.2 4 dp02412_ex9902.htm

    EXHIBIT 99.02
  Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
     
  Press Release  
     

FIRST QUARTER 2006 RESULTS DATE NOTIFICATION
27 April 2006

Basingstoke, UK and Philadelphia, US – 11 April 2006 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) will announce first quarter 2006 earnings on Thursday 27 April 2006.

Results press release will be issued at:   12:00 GMT / 07:00 ET
     
Investor conference call time:   14:00 GMT / 09:00 ET

Live conference call for investors:

Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:00 GMT/9:00 ET.

Please RSVP ssalah@uk.shire.com (T: +44 (0)1256 894 160) for this conference call.

The details of the live conference call are as follows:

UK dial in   0800 953 1444 (free call)
     
US / Canada dial in   US1 866 295 3947 (toll free)/ Canada: 1 866 476 5524
     
International dial in   +44 (0) 1452 561 394
     
Password/Conf ID   7860599

Live Webcast:

The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website.





Replay:

A replay of the presentation will be available for two weeks. Details are as follows:

UK dial in   0845 245 5205
International dial in   +44 (0) 1452 55 00 00
Pin code   7860599#
Webcast replay   www.shire.com, in the investor relations section

If you have any problems accessing this, please contact: Souheil Salah on: +44 (0) 1256 894160

For further information please contact:

Investor Relations   Souheil Salah (Rest of the World)    +44 1256 894 160
  Heidi Wunder (North America)    +1 484 595 8970

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system, gastrointestinal, general products and human genetic therapies - all being areas in which Shire has a commercial presence. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. Shire’s strategy is to develop and market products for specialty physicians. Shire’s in-licensing and merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com

-----END PRIVACY-ENHANCED MESSAGE-----